$8.75
-0.150 (-1.69%)
At Close: Jun 03, 2026
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
11:00am, Saturday, 12'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceut
LOS ANGELES, CA / ACCESSWIRE / October 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceut
The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
11:00am, Thursday, 10'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceut
LOS ANGELES, CA / ACCESSWIRE / October 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
LOS ANGELES, CA / ACCESSWIRE / October 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
LOS ANGELES, CA / ACCESSWIRE / October 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
11:00am, Sunday, 06'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
LOS ANGELES, CA / ACCESSWIRE / October 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
11:00am, Friday, 04'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
11:00am, Wednesday, 02'nd Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmaceuti
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Law Violations
11:00am, Monday, 30'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmace
LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmace
The Schall Law Firm Urges Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws
11:00am, Saturday, 28'th Sep 2024
LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ARS Pharmace
Sign In
Buy SPRY